Transfusion Medicine Reviews
Volume 24, Issue 2 , Pages 151-152 , April 2010

The Usefulness of Pathogen Inactivation During an Outbreak of the New Strain of Influenza (H1N1)

  • Hiroto Narimatsu

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Hiroto Narimatsu, Division of Social Communication System for Advanced Clinical Research, The Institute of Medical Science, the University of Tokyo 4-6-1, Shirogane-dai, Minato-ku, Tokyo, Japan 180-8649.
    • ,
  • Koichiro Yuji

References 

  1. Drastic decrease in Kansai region blood donations; "The need to curtail blood transfusions" say the Ministry of Health, Labor and Welfare; Medical Institutions; New Strain Influenza. Asahi Shinbun. 2009 May 23
  2. Zimrin AB, Hess JR. Planning for pandemic influenza: Effect of a pandemic on the supply and demand for blood products in the United States. Transfusion. 2007;47:1071–1079
  3. Pandemic flu: A national framework for responding to an influenza pandemic. [Home page on the internet]. 22 [cited 2009 July 7]; Available from http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_0807342007;
  4. Kumar V, Lockerbie O, Keil SD, et al. Riboflavin and UV-light based pathogen reduction: Extent and consequence of DNA damage at the molecular level. Photochem Photobiol. 2004;80:15–21
  5. Picker SM, Speer R, Gathof BS. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion. 2004;44:320–329
  6. Home page of Cerus Corporation [Home page on the internet]. cited 2009 June 24 Available from http://www.cerus.com/index.cfm2009;
  7. Webert KE, Cserti CM, Hannon J, et al. Proceedings of a consensus conference: Pathogen inactivation-making decisions about new technologies. Transfus Med Rev. 2008;22:1–34
  8. 2007, 2008 Proceedings summary of the Pharmaceutical Affairs and Food Sanitation Council's Haematology Division Operation Committee/Safety Technology Investigation Council. [Home page on the inernet] 2008 [cited 2009 June 21]; Available from: http://www-bm.mhlw.go.jp/shingi/2008/12/dl/s1225-15p.pdf
  9. Osselaer JC, Messe N, Hervig T, et al. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion. 2008;48:1061–1071
  10. Osselaer JC, Cazenave JP, Lambermont M, et al. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang. 2008;94:315–323

PII: S0887-7963(09)00125-4

doi: 10.1016/j.tmrv.2009.12.001

Transfusion Medicine Reviews
Volume 24, Issue 2 , Pages 151-152 , April 2010

Article Tools